Evidence map›Paper›PMID 42260100›Full record

Trial reportNature medicine2026

Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial.

Richard E Pratley, Douglas Scott Denham, Rupal Trivedi, Elaine Watkins, Lisa Connery, Jennifer Barnes, Dongzi Yu, Janet Hong, Christopher Simard, Kimberly Umans and 3 more

Abstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Richard E PratleyAdventHealth Translational Research Institute, Orlando, FL, USA. Richard.Pratley.MD@AdventHealth.com.ORCID http://orcid.org/0000-0002-2912-1389
Douglas Scott DenhamFlourish Research - San Antonio, San Antonio, TX, USA.
Rupal TrivediFlourish Research - Chicago, Chicago, IL, USA.
Elaine WatkinsProSciento, Inc., Chula Vista, CA, USA.
Lisa ConneryAMR Clinical, Norman, OK, USA.
Jennifer BarnesScholar Rock, Inc., Cambridge, MA, USA.
Dongzi YuScholar Rock, Inc., Cambridge, MA, USA.
Janet HongScholar Rock, Inc., Cambridge, MA, USA.
Christopher SimardScholar Rock, Inc., Cambridge, MA, USA.
Kimberly UmansScholar Rock, Inc., Cambridge, MA, USA.ORCID http://orcid.org/0009-0006-2717-8265
Lan LiuScholar Rock, Inc., Cambridge, MA, USA.
Giridhar S TirucheraiScholar Rock, Inc., Cambridge, MA, USA.
Jing L MarantzScholar Rock, Inc., Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Loss of lean mass in proportion to total weight loss is observed with incretin mimetic therapies such as tirzepatide and has the potential to adversely affect health and function. Apitegromab is an investigational, fully human monoclonal antibody that selectively inhibits myostatin activation and is, thereby, capable of increasing muscle mass. In the randomized, double-blind, placebo-controlled phase 2 EMBRAZE study, adults with overweight or obesity (n = 102) were randomized 1:1 to receive tirzepatide plus apitegromab (10 mg kg

Indexed as

Antibodies, MonoclonalObesityOverweightTirzepatideWeight LossAdultAntibodies, Monoclonal, HumanizedDouble-Blind MethodFemaleHumansMaleMiddle AgedMyostatinAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedapitegromabMyostatinTirzepatide

Identifiers

PMID42260100
PMCPMC13375528

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.